Following this, Gilead has said it will donate up to 2.4 million bottles of Truvada annually to the US Centers for Disease Control and Prevention (CDC) for use by uninsured Americans at risk of the disease. "Now, we have to focus on making sure people who need PrEP are aware of it and adhere to it".
Gilead Sciences-the pharmaceutical company that holds a patent on the highly effective HIV prevention drug Trvuada, or PrEP-is releasing its hold on the drug earlier than expected, meaning a generic version of Truvada will be available as early as 2020. The majority of Americans who are at risk and who could protect themselves with PrEP are still not receiving the medication.More news: After Trump Invite, Iran Commander Says
Trial results announced in early March show Descovy matched Truvada's effectiveness at preventing infection, and Gilead has said it plans to file the drug with regulators as a result.
Filter Magazine, which first reported the news, said that it had reviewed an email from Douglas Brooks, Gilead's executive director of community engagement, which told investors that the anticipated relinquishment of its exclusive patent on Truvada was set for a year earlier than anticipated.More news: Palestinian killed by Israeli fire in Gaza border clashes: ministry
Gilead has announced it will donate its HIV drug Truvada to a US-government led prophylaxis programme to end the epidemic of the disease. It lists for over $20,000 per year, per individual.
The agreement between the U.S. Department of Health and Human Services and Gilead will last until at least December 31, 2025 and possibly through December 31, 2030, and will provide medication to treat individuals who are at risk for HIV and who are uninsured. In a statement from the PrEP4All Collaboration, Dr. Aaron S. Lord said allowing just one generic manufacturer, Israel-based Teva Pharmaceuticals, to make generic PrEP "will do little to reduce the price in a way that will increase access, and PrEP4All remains suspicious of the terms and lack of transparency surrounding the Teva settlement"'.More news: US issues new warning to ships after 'sabotage' off UAE
Gilead's rights to Truvada hit the headlines in March this year, after the Washington Post reported that United States taxpayers had nearly fully funded CDC work to develop Truvada. Gilead's patent stalled any forward motion on that front, until now. Sign up to our free newsletters and get stories like this sent straight to your inbox.